Department of Pharmacology and Therapeutics, The University of Melbourne, Victoria, Australia; Friends of Science in Medicine, Melbourne, Victoria, Australia.
Friends of Science in Medicine, Melbourne, Victoria, Australia.
J Autoimmun. 2015 May;59:77-84. doi: 10.1016/j.jaut.2015.02.005. Epub 2015 Mar 18.
In 2011 Shoenfeld and Agmon-Levin proposed a new syndrome as a way of grouping together a range of emerging autoimmune diseases with possible adjuvant-associated causes, Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants (ASIA). At present, there is no evidence to suggest that ASIA syndrome is a viable explanation for unusual autoimmune diseases. Since the initial paper, over 80 publications have discussed ASIA. This systematic review examines the research that has been done to investigate whether ASIA is a broad umbrella term with little clinical significance, or whether there is some underlying mechanism which could be utilised to reduce the occurrence of adjuvant mediated disease. Twenty-seven animal, epidemiological and case studies were reviewed. Unfortunately, a robust animal model of ASIA using biologically relevant doses of adjuvants has yet to be defined. It is also apparent that the broadness of the current ASIA criteria lack stringency and, as a result, very few cases of autoimmune disease could be excluded from a diagnosis of ASIA. The current studies involving human cases are so diverse, in both external stimuli and in resulting conditions, that there is currently a lack of reproducible evidence for any consistent relationship between adjuvant and autoimmune condition. The addition of a mandatory criterion requiring temporal association and clinically relevant adjuvant dose would allow better definition of what constitutes a diagnosis of ASIA.
2011 年,Shoenfeld 和 Agmon-Levin 提出了一种新的综合征,旨在将一系列可能与佐剂相关的新兴自身免疫性疾病归类为“佐剂诱导的自身免疫/自身炎症综合征”(ASIA)。目前,尚无证据表明 ASIA 综合征可以解释不常见的自身免疫性疾病。自最初的论文发表以来,已有超过 80 篇出版物讨论了 ASIA。本系统评价研究了已开展的研究,以探讨 ASIA 是否是一个宽泛而临床意义不大的术语,还是存在某种潜在机制可以用来减少佐剂介导的疾病的发生。共回顾了 27 项动物、流行病学和病例研究。不幸的是,使用生物学相关剂量的佐剂来建立 ASIA 的稳健动物模型尚未得到定义。目前 ASIA 标准的宽泛性也缺乏严格性,因此,很少有自身免疫性疾病病例可以排除在 ASIA 诊断之外。目前涉及人类病例的研究在外部刺激和所导致的疾病方面非常多样化,以至于目前缺乏任何一致的证据表明佐剂和自身免疫性疾病之间存在可重复的关系。添加一个强制性标准,要求有时间关联和临床相关的佐剂剂量,将有助于更好地定义 ASIA 的诊断。